Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy

Proceedings of the National Academy of Sciences, Volume 122, Issue 45, November 2025. SignificancePersistent tumor antigen exposure leads to T cell exhaustion during bispecific T cell engager (BiTE) therapy. T cell exhaustion is a condition in which T cells lose the ability to effectively kill tumors. To address this, we have developed a …